ArticleTrials2022
Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.
Peter W Nickerson et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this papercites it